Stay updated with breaking news from Roger Adsett. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Morgan Stanley restated their overweight rating on shares of Insmed (NASDAQ:INSM – Free Report) in a report issued on Friday, Benzinga reports. They currently have a $41.00 price target on the biopharmaceutical company’s stock. A number of other equities research analysts have also recently issued reports on the stock. StockNews.com cut shares of Insmed from […]
Insmed (NASDAQ:INSM – Get Free Report) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported ($1.78) earnings per share for the quarter, missing the consensus estimate of ($1.10) by ($0.68), Briefing.com reports. The firm had revenue of $77.23 million for the quarter, compared to the consensus estimate of $70.23 million. Insmed had a […]
Insmed (NASDAQ:INSM – Get Free Report) released its quarterly earnings results on Thursday. The biopharmaceutical company reported ($1.78) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.10) by ($0.68), Briefing.com reports. The firm had revenue of $77.23 million during the quarter, compared to analysts’ expectations of $70.23 million. Insmed had a […]
Insmed (NASDAQ:INSM – Get Free Report) was downgraded by equities research analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Thursday. Separately, Guggenheim began coverage on Insmed in a research report on Tuesday, July 25th. They set a “buy” rating and a $50.00 price objective for the […]
Insmed Incorporated (NASDAQ:INSM – Get Free Report) saw a significant increase in short interest in July. As of July 15th, there was short interest totalling 9,650,000 shares, an increase of 7.7% from the June 30th total of 8,960,000 shares. Based on an average daily volume of 989,100 shares, the days-to-cover ratio is currently 9.8 days. […]